What does it mean to be
INSIDE AFRICA ?
For us, it encompasses our local staff, decades of on-the-ground experience, strong working relationships with stakeholders of all types, cultural competence and a commitment to the region and its people. Because of this, we’re ready to respond at a moment’s notice to implement locally adapted and staffed studies in sub-Saharan Africa that produce high-quality research.
Visit us at WVC Europe to experience Africa
Visit booth 79 at World Vaccine Congress Europe to meet our team members and experience the sights, sounds and tastes of sub-Saharan Africa. We look forward to discussing how your next research project could benefit from the potential of and our experience in sub-Saharan Africa.
![](https://fhiclinical.com/wp-content/uploads/2022/07/Headshots_600x600_72dpi_0002_Sanchia-Theron.jpg)
Sanchia Theron
Global Head, Medical Affairs
![](https://fhiclinical.com/wp-content/uploads/2022/07/Headshots_600x600_72dpi_0006_Ghiorghis-Belai.jpg)
Ghiorghis (George) Belai
Vice President, Global Strategy
![](https://fhiclinical.com/wp-content/uploads/2022/08/Headshots_600x600_72dpi_Karen-Insley.jpg)
Karen Insley
Senior Account Development Manager,
Client Solutions
presentation
![](https://fhiclinical.com/wp-content/uploads/2022/07/Headshots_600x600_72dpi_0002_Sanchia-Theron.jpg)
Oct 14, 2022 | 10:30 AM CEST
Tuberculosis (TB): The Silent “Pandemic” The World Has Forgotten
Presenter: Sanchia Theron, Global Head, Medical Affairs
Location: Level 2, Room 6
Tuberculosis (TB) is second only to COVID-19 among the infectious disease-related mortality rates worldwide. The need for effective, safe TB vaccines and treatments remains a global health priority, especially in the midst of increasing cases of multidrug-resistant TB (MDR-TB). In this presentation, Sanchia Theron will discuss the progress that the health and research community has made so far in addressing TB and reaching the goals of the End TB Strategy. Based on FHI Clinical’s experience with TB research, particularly in sub-Saharan Africa, the discussion will also include strategies to overcome research challenges presented by hard-to-reach populations, MDR-TB and established and emerging policies for TB preventive treatment (TPT).